Tag Archives: seeking-alpha

Best 20+ Odds-On Oil And Gas E&P Stocks, As Seen By Fund Clients Of Market-Makers

Summary With Crude Oil Prices in mid $40s, up from high $30s, a turn may be coming for independent new extraction technology explorers and producers. Tough times of world price cuts by more than 60% leave only the strongly resourced, well-financed, advantaged survivors. Their rebound time may be near at hand, as seen in large-volume order flows from big-$ investment portfolio managers. Who are the best positioned energy stock survivors? The best candidates are indicated by the “order flow” from big-money “institutional” clients of market-making investment banks, suggesting high-probability additions to their billion-dollar portfolios. (If you have read this story before, please skip directly to Figures 1 and 2) The fund-management clients have extensive, experienced research staffs constantly looking for sound, long-term, rewarding investment candidates. The presence of their interest in these issues typically is a disruptive influence to markets because of their size of transaction orders. The “regular way” every-day “retail” investment transactions largely get handled (or mis-handled) by automated systems developed by advances in transaction technology. Those advances have cut the costs for individual investors to fractions of a cent per share, compared to pre-Y2K costs of sometimes a dollar or more a share. But big-volume “block” orders can’t be handled that way without crashing the system. They must be negotiated among other big players in this very serious game. That is where the market-maker firms play an important role. The MM firms know which players own what, and have a good idea of what their current appetites may be. Usually differences of opinion as to appropriate valuations for specific stocks are not evenly balanced enough among these fund-manager players to instantly “cross” trades of tens or hundreds of thousand shares. So the MM firms even out the balance between buyers and sellers by temporarily committing their own capital. But they don’t go naked. The at-risk commitments of MMs are always hedged in one way or another, and the cost of that protection is borne by the trade-originating client. It is built into the trade “spread” between the single per-share price of the block deal and the current “regular-way” market price. The cost of the hedge deal and the structure it takes is negotiated between the arbitrage artists of the MM firms block trade desks and “Prop” trade desks in open competitive combat. What it costs and the shape it takes reveals what these well-informed, profiting antagonists believe is possible to occur between now and the time it may take to unwind the contracts on derivatives used in the hedge. That often could be as much as a few months. So the range of possible prices implied is not an instantaneous, trivial spread. Often it is 10% to 20% or more, given the uncertainties involved in the underlying security. Where today’s market quote lies in that forecast range may be important in the stock’s future movement. The first thing to remember about this analysis is that it is a “snapshot” of current conditions, dominated by price relationships that are likely to change in coming days, weeks, and months. Those changes are typically the main point on most player scorecards. This article is not an evaluation of how “good” the companies involved are at managing, competing, profiting, or treating their employees or shareholders. It simply tells how well on this date the perceived prospects for each equity investment security candidate may be, compared with those of others, on a variety of matters and measures of concern. This is not a long-term hold evaluation. But it could identify overlooked, near-term value opportunities to be captured by active investing management. The place to start in the analysis is with the market character presented by each of the best dozens of stocks out of the hundred or more once on the scene. Figure 1 tells those stories: Figure 1 (click to enlarge) Source: Yahoo Finance, Peter Way Associates Items of concern here have to do with how easy it may be to get out of a position if in a hurry, and what the cost of doing so might entail. The first four columns do so by calculating how many market days’ average volume of trading at the current price it would take to completely replace existing shareholders. That is not expected to happen, it just gives a realistic comparative measure of how easy or difficult it might be to extricate oneself from an unwanted position. Extreme examples here are Enbridge (NYSE: ENB ), with a million-share-a-day trading volume to take over 3 years to clear its huge $34 billion of outstanding shares. At the other extreme is the market-tracking SPDR S&P 500 Index ETF (NYSEARCA: SPY ) with a five times as large ownership value, but 139 million share daily volume doing the task every 6 days. Yes, Sasol, Ltd.(NYSE: SSL ) shows a capital turn in over a thousand days, but it is a South African company and its principal share trading takes place in markets outside of the US. Another dimension of the distress of departure is what the typical trade cost may be, which can be indicated by the stock’s bid-offer spread. These days that tends to be a tiny fraction of the value per share during normal market hours. But every investor needs to protect themselves against errant or intentional malicious spread quotes by always using price limit orders when changing positions, instead of unrestrained “at market” orders. The other useful matter of perspective in Figure 1 is a sense of each stock’s current price in relation to its past year’s trading range, and a sense of how the size of that range compares to alternative investments. The Range Index [RI] tells what proportion of the whole range lies below the stock’s current price. A low past RI indicates a price depressed in comparison with earlier trading, and a high past RI tells of a stock that has been on the move up near new highs. The range size is a dimension only discussed in the media as an example of either triumph or disaster, but rarely in company of comparable alternatives. The average sizes here in this group are over 100%, meaning that a double in price (or a 50% drop) is commonplace. The latter phase just mentioned of that change scares most investors, as it should. But it is an all-too-common condition, often setting the stage for the former-mentioned next joy. So what does come next? That is what everyone wants to know, and not knowing for sure, everyone guesses at. MMs have a leg up in the game, since they know what their clients, with the money muscle to move markets, are trying to do. The well-informed protection sellers provide deals very likely to assure themselves of nice profits, with little likelihood of having to deliver on the immunization. A done deal tells where the extreme possibilities lie. Those outer limits have been shown in a high proportion of instances to be quite reachable. The agile, fleet-of-foot protection sellers usually manage to profitably transfer the accepted risks to others and get on to the next deal before having to make good on their bet this time (again). So the price range forecasts implied by the capital-risk hedging can be useful information to others interested in the stocks or ETFs involved. To determine how useful the current forecasts may be, we look back to how similar prior forecasts (made without knowledge of what next happened) were actually treated by a merciless marketplace. Figure 2 tells the particulars, and provides a means of ranking the attractiveness for wealth-building active investors. Figure 2 (click to enlarge) source: Peter Way Associates, blockdesk.com At the outset, something about Figure 2 should be understood. Columns (2) and (3) are current-day forecasts, implied by the self-protective actions of market-making professionals in the course of serving transaction orders from big-$ clients at or near column (4). All the remaining columns are matters of record of how prior forecasts for the subjects in column (1), made live in real-time over the past 5 years, have actually performed. Those prior forecasts were only those of the total available in (12) that had upside-to-downside proportions like the current forecast, described in (7). The Range Index [RI] tells what percentage of the whole forecast range lies below (4). The size of this sample set of forecasts has potential statistical implications if it is small. Few of the subjects of Figure 2 have that problem, and none of the top ten. This is the importance of column (12), a dimension pertinent to all references to prior performance. The number of forecasts available in any subject’s current situation is a function of the current Range Index. More will be available when the RI is in the 30-50 area and fewer when the subject is at extremes, nearing zero or 100. Market price behavior varies from subject to subject for a variety of reasons, so attractiveness based solely on RI can be misleading. That makes this kind of analysis in detail important. Additional evaluations may be useful when RIs are at or near extremes. The historical data of Figure 2 differs significantly from “back-test” data because it is based on the live forecasts made at the time, when subsequent price action confirmations were not available. The usual back-test data only is presented when full knowledge of the outcomes is at hand. That makes it impossible to know what kind of decisions might have been made at the time. This historical data applies our standard TERMD portfolio management discipline to buy positions of all column (12) sample forecasts. TERMD has been in existence for over a decade. It is more fully described below . For example, column (6) is an average of the worst-case price drawdowns from the closing price of the subject on the next market day after the forecast, over the holding period up to the position’s closing. This is the relevant measure of risk, since it identifies the greatest loss likely to be taken at the point of maximum emotional stress. Column (8) on the other hand, tells what proportion of the sample forecasts were able to recover from the (6) experience and be closed out profitably by reaching (5) sell targets or by TERMD’s holding period time limit of 3 months. Column (5) relates (2) to (4). Column (9) tells what the closeouts of all subject sample forecast positions averaged, profits, net of losses (by geometric mean). The CAGR of these experiences in (11) uses the average holding period of (10) in conjunction with (9). The promise of (5) is tested by (9) in (13). The proportion of (5) to (6) is shown in (14). Overall, a figure-of-merit is calculated in (15) by odds-weighting (5) by (8) and (6) by (8)’s complement, further conditioned by the frequency of (12). The table’s contents are ranked by (15). That ranking is what ordered Figure 1. What it all suggests Without getting into a detailed discussion of the attributes of interest, comparisons of the best-odds (most attractive by column 15) ten E&P stocks with a market-average tracking alternative ETF, SPY, show upside price changes (5) almost twice as large, and risk exposures (6) about one and a half times as large. Their forecast history translates into CAGR performances (11) four times as good as market results, with odds for profit outcomes (8) about the same, 8 out of every 10. But comparisons with the best 20 propositions from the measurable overall equity population of 2711 alternatives, puts the Oil&Gas E&P stocks at a disadvantage. The difference lies not in the size of the payoff promise, but in its follow-through. The average price gains of the population’s best stocks surpassed their forecasts +11.4% to +10.4% , with 9 out of every 10 experiences profitable, and average holding periods to reach payoffs shorter by 36 market days to 41, or roughly 7 weeks compared to 8. That leads to a CAGR past result (11) of 114%, double the comparable measure of +55% for the E&Ps. Conclusion I appears that there is sufficient early action in volume trade transactions in Oil & Gas independent Explorers and Producers to elevate expectations for their coming stock prices to a level more than competitive with passive market-index ETF investing. Best candidates may be PDC Energy (NASDAQ: PDCE ) and Matador Resources (NYSE: MTDR ). Perhaps in coming weeks this activity will strengthen and raise the prospects higher. But at present there are a number of alternative equity investments that substantially surpass the typical prospects of the best of this group. Commitments among those alternatives should be better rewarded. Patience, my energy friends. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Biotech ETFs In A Bull Market: Positioning For A Q4 Rally

Summary Biotech ETFs have rallied off a triple bottom. The XBI is still the leader up 22.64% YTD with a high turnover small cap portfolio. Position new buys with two complementary ETFs. Biotech ETF Trends: What to watch for in a 2015 bull market The biotech 15%+ correction and increased volatility has unnerved many investors and traders. Risk remains high due to macroeconomic concerns and recent weakness in the healthcare sector. Momentum is gone and many high-flying emerging stocks have been crushed. But the bull market is intact and since late last Friday buyers were coming into the favored stocks. The biotech sector is still the market leader. Large cap biopharmaceutical stocks have been hit and many are in the red and should recover, but they are too earnings dependent to make huge moves in Q4 so we favor mid and small caps for trading and new positions. Mid-caps are favored because many have strong pipelines with potential for clinical breakthroughs and M&A action. Stock picking will get harder so for re-balancing portfolios and new positions consider ETFs. It is very difficult to track or analyze ETF holdings except to note style i.e. large cap, small cap, diagnostics, services etc. If you believe we have bottomed in biotech for the year and that we are poised for the year-end rally, this could be a good time to accumulate positions. The action this week has been favorable but the technicals must hold in a sell-off. Healthcare has the best of both worlds in this market: growth from biotech/devices and stability from services and tools. Here is where we stand on major biotech ETFs: The First Trust NYSE Arca Biotechnology Index ETF ( FBT) 115.38 up 13.1% YTD, the iShares Nasdaq Biotechnology ETF ( IBB) 350.72 up 15.62% YTD, the SPDR Biotech ETF ( XBI) 228.67 up 22.64% YTD. Here is a summary of ETF trends to watch: The biotech sector is more dependent on healthcare economics so the Health Care Select Sect SPDR ETF (NYSEARCA: XLV ) needs to hold or move in tandem with biotech. XLV holdings include both biotech and large cap drugs: Johnson & Johnson ( JNJ), Pfizer Inc. ( PFE), Gilead Sciences, Inc. ( GILD), Merck & Co Inc. ( MRK), Amgen Inc. ( AMGN) etc. The small cap “equal weighted” XBI continues to be the leader although it can be more volatile particularly in down markets. The holdings include more speculative stocks that are turned over rapidly probably with a lot of help from algorithms: Anacor Pharmaceuticals, Inc. ( ANAC), Exelixis, Inc. ( EXEL), KYTHERA Biopharmaceuticals ( KYTH), Dynavax Technologies Corporation ( DVAX), Sarepta Therapeutics, Inc. ( SRPT) etc. IBB favors well known large caps among the top ten positions. Holdings include all the usual suspects adding up to 59% of total: Celgene Corporation ( CELG), AMGN, GILD, Regeneron Pharmaceuticals, Inc. ( REGN), Biogen Inc. ( BIIB) etc. It tracks the five-star Fidelity Biotechnology Portfolio Fund (MUTF: FBIOX ). FBT has shifted its strategy over the past year and has become broadly diversified with holdings in tools and services. Well known stocks include : Incyte Corporation ( INCY), Vertex Pharmaceuticals Incorporated ( VRTX), REGN, AMGN and diagnostic plays Myriad Genetics, Inc. ( MYGN), Qiagen N.V. ( QGEN). The technicals had rolled over into a downward channel but have recovered this week above the triple bottom for 2015 and at the SMA 200. Review the Rayno Biopharmaceutical Portfolio for new ideas and a comparison to the ETFs. For new investors and rebalancing healthcare portfolios we would favor complementary positions such as a fund FBIOX or IBB for core with XBI as a complement. Review our previous articles on Life Science ETFs which provides information on additional healthcare funds and ETF performance. Disclosure: I am/we are long GILD, FBIOX. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Additional disclosure: We use XBI long and short for trading and rebalancing portfolios. Share this article with a colleague

How To Tell The Difference Between The Graham Formula And The Graham Number

This article will aim to help you as a reader understand the difference between the Graham Formula and the Graham Number. The Graham Formula is the formula which Benjamin Graham provided in his classic book The Intelligent Investor. The Graham Number is a figure used by some investors as an upper limit to how much an investor should pay for a stock. The Graham Number formula was never actually provided by Benjamin Graham. Even though the Graham Number isn’t used in the ModernGraham approach, the figure is now provided with each individual ModernGraham valuation. (click to enlarge) Often I get questions about the Graham Formula versus the Graham Number. There seems to be some misunderstanding out there between the two concepts, and this article will aim to help you as a reader understand the difference between the Graham Formula and the Graham Number. Both figures can be useful in their own ways, and can be combined in the ModernGraham approach. What is the Graham Formula? The Graham Formula is the formula which Benjamin Graham provided in his classic book The Intelligent Investor . Specifically, the formula Graham recommended is: According to Graham, this formula resulted from a study of various valuation methods and is to be considered an effective shorthand way of estimating the intrinsic value of stocks. The formula should result in figures “fairly close to those resulting from the more refined mathematical calculations.” Where does the Graham Formula Come From? Graham placed the Graham Formula in Chapter 11 of The Intelligent Investor , titled “Security Analysis for the Lay Investor: General Approach.” This chapter deals specifically with finding ways to simplify some of the complex mathematical analysis methods which have grown in popularity over the years. After dealing with analyzing bonds and preferred stocks, Graham addresses the issue of valuing stocks, beginning with the sentence “The ideal form of common-stock analysis leads to a valuation of the issue which can be compared with the current price to determine whether or not the security is an attractive purchase.” Graham then went into some detail regarding how many valuation methods utilize future estimates of various figures such as sales, operating margin, etc. in order to then capitalize those figures back to the present in order to determine a value based on the future earnings of the company. However, he then said that “The reader will note that quite a number of the individual forecasts were wide of the mark.” Further, the present value of future earnings is widely dependent on various factors such as: General Long-Term Prospects. Management. Financial Strength and Capital Structure. Dividend Record. Current Dividend Rate. Discussion of each of those factors is beyond the intended scope of this particular article, but together those items constitute items that an analyst must consider when determining an intrinsic value. With all of that in mind, it makes sense that Graham then proceeded to provide the Graham Formula as a way to simplify some of the process for the lay investor. Analysts can spend a lot of time considering each and every little detail about what they think a company is going to do, generating complex mathematical formulas and scenarios in order to determine a value, but Graham’s formula is intended to help the average Intelligent Investor to estimate a value while making as few assumptions about the company as possible. What about the Footnote? Immediately after listing the formula itself, Graham stated that “The growth figure should be that expected over the next seven to ten years.” He also included a footnote on that sentence. The footnote reads: Note that we do not suggest that this formula gives the “true value” of a growth stock, but only that it approximates the results of the more elaborate calculations in vogue.” Some have taken that footnote to mean that the Graham Formula should not be used for estimating an intrinsic value, but I consider the footnote to be more of a reminder from Graham that the calculation of an intrinsic value is not an exact science and cannot be done with 100% certainty. Rather, the investor can only estimate at the intrinsic value due to the vast number of variables involved. Graham provided this formula specifically as a way to approximate the more complex formulas used in an analysis in order to give a “foreshortened and quite simple formula for the valuation of growth stocks, which is intended to produce figures fairly close to those resulting from the more refined mathematical calculations.” Therefore, the Graham Formula is to be used for estimating intrinsic value within a margin of safety which will accommodate the possibility of error in calculation. What is the Graham Number? The Graham Number is a figure used by some investors as an upper limit to how much an investor should pay for a stock. Here’s an example of how some investors use the Graham Number when analyzing dividend aristocrats. The Graham Number is calculated using this formula: According to the Graham Number calculation, the price must be below the square root of the product of 22.5, the Earnings Per Share, and the Book Value Per Share. Where does the Graham Number Come From? The Graham Number formula was never actually provided by Benjamin Graham. Rather, it seems to be engineered out of one of Graham’s recommended requirements for the Defensive Investor. In Chapter 14 of The Intelligent Investor , Graham provided a list of suggested criteria to help the Defensive Investor find quality securities for consideration. Those criteria are as follows: Adequate Size of the Enterprise A Sufficiently Strong Financial Condition Earnings Stability Dividend Record Earnings Growth Moderate Price / Earnings Ratio Moderate Ratio of Price to Assets In the seventh criteria, Moderate Ratio of Price to Assets, Graham says that “Current prices should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiple of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5.” The 22.5 number comes from the product of his suggested maximum price to earnings ratio of 15 and the suggested maximum book value of 1.5. Somewhere along the line, analysts took this suggestion from Graham and extrapolated it into the Graham Number. The Graham Number is Only a Shorthand Version of the Graham Requirements for Defensive Investors. It is my belief that the Graham Number is only a way to easily and quickly screen companies to be used by individual investors not interested in applying all of Graham’s suggested investment techniques. In some ways it seems to be a figure created to simplify Graham’s work into a single recommendation, which to me seems to miss the overall point Graham is trying to make altogether. The Defensive Investor requirements are intended to assist the investor in narrowing down his potential list of investments to only those that are of the highest quality. Graham provided a list of suggested requirements to achieve that purpose, while he specifically provided the Graham Formula as a metric for estimating the intrinsic value of companies. Why would Graham have listed the suggested criteria in an area separately from the formula if he did not intend both items to be used? What Approach Does ModernGraham Use? Here on ModernGraham, I’ve developed our approach to utilize the full breadth of Graham’s recommendations. This is through utilizing both the suggested selection criteria to narrow down the list of potential investments and through the use of the formula to estimate an intrinsic value. Doing this allows the investor to narrow down the focus to a select number of companies and then generate an estimated intrinsic value based on the Graham Formula for comparison to the current price. Each ModernGraham valuation of a company begins with determining whether it is suitable for either the Defensive Investor or the Enterprising Investor, based on a modernized version of Benjamin Graham’s suggested selection criteria for each investor type. Here’s a great post on how you can determine which type of investor you are. After that step is completed, the valuation continues to determining an estimated intrinsic value for the company based on the ModernGraham formula. The ModernGraham formula has been modified slightly from the Graham Formula, only in the sense that it uses a weighted-average of five years of earnings data (EPSmg). The rationale is that Graham suggested using a normalized earnings per share figure in order to smooth out the effects of the business cycle, and also specifically suggested taking an average of earnings per share data when using the figure in analysis. You can learn more about how to estimate a growth rate in this post. Here’s the ModernGraham Formula: This formula is specifically intended to provide only an estimate of the company’s intrinsic value and must be utilized in tandem with a margin of safety because it does not provide an exact figure but only approximates some of the more complicated valuation methods. ModernGraham utilizes multiple layers of safety margins including: Maximum possible estimated growth rate of 15% Estimated growth rate is reduced by 25% To receive a rating of “undervalued” a company must be trading at 75% or less of its intrinsic value. To receive a rating of “overvalued” a company must be trading at 110% or more of its intrinsic value. Each valuation is intended to be a useful source for investors to utilize when conducting research into investment opportunities, and after the first two steps of the ModernGraham analysis, investors are encouraged to continue their research in order to determine if the opportunity is right for their own individual situation. Where Can You Find the Graham Number? Even though the Graham Number isn’t used in the ModernGraham approach, the figure is now provided with each individual ModernGraham valuation. In addition, as of today all new valuations will include a chart showing the Graham Number over time in comparison to the stock price. For those investors who place an emphasis on utilizing the Graham Number, this can be a great tool to see how the strategy has performed over time with respect to the specific company. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.